BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AnaMar Medical Raises SEK 75 Million in New Financing


11/6/2008 6:48:31 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--The Swedish biotech company AnaMar Medical raises SEK 75 millon in a rights issue to finance continued development of its projects in chronic joint diseases. In a first step, the funds will finance a phase I study of a drug candidate developed for rheumatoid arthritis.

”We are happy to have successfully secured SEK 75 million in new financing in the current financial climate. It’s an acknowledgement that our principal owner shares our confidence in our projects. With this financing in place, we can take the first step into the clinic,” says AnaMar’s CEO Owe Gårlin. “First in line is a compound that is being developed for rheumatoid arthritis for which we will submit a Clinical Trials Application early next year. Our next project is also approaching studies in man.”

The funds are provided through a rights issue guaranteed by AnaMar’s principal owner Koncentra Holding AB. All shareholders are invited to participate in the rights issue.

The drug candidate that is currently being prepared for clinical studies is developed in the project AM240 MCR and is an orally bioactive small molecule compound that in preclinical studies has been shown to suppress inflammation and cartilage destruction in disease models for rheumatoid arthritis. The compound has also shown effect on pain.

The other project, AM260 TASS, is a compound that targets a receptor system which is known to be involved in the immunomodulation process. The main indication is treatment of rheumatoid arthritis. There are currently no drugs on the market using the target receptor for the chosen indication.

AnaMar’s focus is the identification and treatment of chronic joint disease, in particular rheumatoid arthritis. The company was founded in 1998 to commercialize research by the professors Dick Heinegård and Tore Saxne at the University in Lund, Sweden. Today, AnaMar has a broad portfolio of five drug development projects and three biomarkers, originating from academic institutions and selected partners.

AnaMar’s largest owners are Koncentra Holding AB and LinkMed AB.

This information was brought to you by Cision http://www.cisionwire.com

Contact:

AnaMar Medical AB Owe Garlin, CEO + 46 31 732 41 42

Source: AnaMar Medical AB

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES